Translational perspective
High-density lipoprotein (HDL) biogenesis occurring in the process of removing excess cellular cholesterol is known to be the most cardiovascular protective action of HDL, but there is no effective therapy to increase HDL biogenesis. This study provides evidence that a novel apolipoprotein A (apoA)-I binding protein desmocollin 1 (DSC1) acts as a negative regulator of HDL biogenesis and that DSC1 expression levels in atherosclerotic lesions are associated with lesion progression. Our findings suggest that development of monoclonal antibodies or small molecules inhibiting apoA-I-DSC1 interactions would be a viable strategy to increase HDL biogenesis within the atherosclerotic plaque.
Introduction
Atherosclerotic cardiovascular disease (ASCVD) is characterized as a cholesterol deposition-driven chronic inflammatory disease, and the maintenance of cholesterol balance in atherosclerotic lesions is crucial for the prevention and treatment of ASCVD. 1, 2 The major mechanism for cholesterol-laden foam cells to reduce cholesterol burden is to generate high-density lipoprotein (HDL) particles: Adenosine triphosphate (ATP)-binding cassette transporter A1 (ABCA1) up-regulated in the foam cells creates specialized microdomains in the plasma membrane (PM) to remove excess cellular cholesterol, where an extracellular lipid acceptor apolipoprotein A-I (apoA-I) binds and solubilizes the domains in order to form apoA-Ilipid complexes termed nascent HDL particles. [3] [4] [5] These particles increase in size by taking up more cholesterol via other lipid transporters such as ATP-binding cassette transporter G1 and scavenger receptor class B type I prior to release into the circulation and delivering cholesterol to the liver for disposal or recycling, known as reverse cholesterol transport. 6 The rate-limiting step of HDL biogenesis is the binding of apoA-I to ABCA1-created PM microdomains, 4 but the structural and molecular basis of the domains has not been fully determined. In addition, normal apoA-I binding to cells expressing a dysfunctional or dysregulated ABCA1 indicates the presence of ABCA1-independent apoA-I binding sites on the PM. 7, 8 In order to isolate and characterize apoA-I binding PM microdomains, we established a new and unbiased method and identified desmocollin 1 (DSC1) as a novel apoA-I binding protein that is highly expressed in atherosclerotic lesions and inhibits HDL biogenesis.
Methods
Methods are available in the Supplementary material online.
Results

Isolation of a novel apolipoprotein A-I binding domain on the plasma membrane
A large quantity of primary human cells is required for the isolation of physiologically relevant PM microdomains; therefore, we set up our experimental protocol using primary human skin fibroblasts (HSFs). The cells were incubated for 24 h with 22(R)-hydroxycholesterol/9-cis-retinoic acid to up-regulate ABCA1 and promote apoA-I binding (see Supplementary material online, Figure S1 ), followed by incubation with apoA-I for 1 h at 4 C to allow apoA-I binding only to specific and initial target sites. After linking protein-protein interactions using a membrane-impermeable cross-linker 3,3 0 -dithiobis(sulfosuccinimidylpropionate), the cells were homogenized and centrifuged at 3000 g to eliminate heavy subcellular organelles like nuclei and mitochondria. The supernatant was subjected to discontinuous sucrose gradient centrifugation to separate the other subcellular organelles. 9 Two bands were visible after the centrifugation and 10 fractions were collected to obtain an apoA-I-enriched PM fraction ( Figure 1A ). Plasma membrane marker proteins and apoA-I were predominantly localized in the 8th fraction that also contains a large amount of endoplasmic reticulum membrane and small amounts of Golgi and lysosomal membrane proteins ( Figure 1B) . For further purification, aggregates in the 8th fraction were dissociated by sonication prior to performing anti-apoA-I immunoprecipitation. As shown in Figure 1C , apoA-I was detected exclusively in the pellet devoid of endoplasmic reticulum, Golgi, and lysosomal membrane markers. Furthermore, two PM proteins, caveolin and ABCA1, were excluded from the pellet, indicating that the apoA-I-associated PM domains purified under our experimental conditions are different from the previously proposed PM domains required for HDL biogenesis as ABCA1-created PM domains and caveolincontaining PM domains (caveolae) have been known to contribute to nascent HDL formation and HDL maturation, respectively.
10,11
Characterization of the apolipoprotein A-I binding domain
Throughout the purification procedure, no detergent was added, making it possible to investigate lipid composition of the purified apoA-I-associated PM domains. Total lipids extracted from the domains were analysed for seven major lipid classes in eukaryotic PM: phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), sphingomyelin (SM), and cholesterol. Figure 1D shows that the most abundant lipid was cholesterol (6.01 nM/mg cell protein ± 1.36), followed by SM (2.65 ± 0.32), PS (1.35 ± 0.38), PC (1.34 ± 0.34), and PE (0.64 ± 0.32). With the amount of purified sample from 1 mg cellular protein measured prior to the sucrose gradient centrifugation, PI and PG were not detectable. The enrichment of cholesterol and SM upholds the domains as a candidate for an apoA-I binding site, as cholesterol is the major target of apoA-I, and HDL particles contain a high proportion of cholesterol and SM. 12 In order to determine the protein profile of the purified domains, immunoprecipitation of the 8th fraction was performed with or without anti-apoA-I antibody prior to separating the precipitated proteins on an sodium dodecyl sulfate-polyacrylamide gel. Silver staining of the gel shows protein bands precipitated along with apoA-I ( Figure 1E) . To see whether ABCA1 activity is required for apoA-I to co-precipitate the proteins, Tangier disease (TD) skin fibroblasts expressing a dysfunctional ABCA1 were compared with normal human skin fibroblasts. TD fibroblasts had only 18% of the apoA-I-mediated cholesterol efflux ability of normal fibroblasts, but the profile of co-precipitated proteins from TD fibroblasts was similar to that from normal fibroblasts ( Figure  1E ). This supports the concept that the interaction between apoA-I and co-precipitated proteins is independent of ABCA1. To identify coprecipitated proteins, the entire 2nd lane of the gel in Figure 1E was processed for proteomic analysis. The proteome contained 96 proteins including the major desmosomal proteins: desmoglein (DSG) 1 and 3, DSC 1, plakophilin 1, plakoglobin, and desmoplakin (see Supplementary material online, Table S1 ). Desmosomes are located in cholesterol-and SM-rich PM domains, and the assembly of desmosomes is dependent on cholesterol content. 13, 14 These results suggest that apoA-I may bind to a desmosomal protein.
Specific binding between apolipoprotein A-I and desmocollin 1
Among desmosomal proteins identified, DSC1 is dispensable for the assembly of desmosomes. 13, 15 In addition, the cellular localization of . . . . . . . . . . .
DSC1
is not restricted to cell-cell junctions as shown in Supplementary material online, Figure S2 and as previously reported. 16 These observations suggest that DSC1 may have roles other than desmosome assembly, and we postulated DSC1 as an apoA-I binding partner. To test this, primary HSFs were incubated with apoA-I for 1 h at 4 C prior to lysis. The lysate was subjected to immunoprecipitation using anti-apoA-I, anti-apoB, or no antibody, followed by anti-DSC1 immunoblotting. DSC1 was precipitated only by anti-apoA-I antibody (see Supplementary material online, Figure  S3A ). This binding occurred at 4 C without a chemical cross-linker, indicating specific binding between DSC1 and apoA-I. To visualize the binding, primary HSFs were incubated with Alexa Fluor 647-conjugated apoA-I for 1 h at 4 C, fixed, and stained for DSC1 using anti-DSC1 antibody. Confocal microscopic images of the cells show a high degree of co-localization between DSC1 and apoA-I (see Supplementary material online, Figure S3B ). For further validation, HEK293 cells transfected with DSC1b expression plasmids (pDSC1b) were incubated with apoA-I for 1 h at 37 C prior to lysis.
The lysate was subjected to immunoprecipitation using anti-DSC1, anti-DSG1, or no antibody, followed by anti-apoA-I immunoblotting. This reciprocal immunoprecipitation confirmed the specificity of apoA-I-DSC1 binding ( Figure 2A) . To see the binding in live cells, HEK293 cells expressing green fluorescent protein (GFP)-tagged DSC1b were incubated with Alexa Fluor 647-conjugated apoA-I for 30 min at 37 C prior to washing unbound apoA-I out, followed by capturing time-lapse live cell images. DSC1 and apoA-I clearly colocalize in live cells ( Figure 2B ). Time-lapse images display dynamic and rapid movements of the apoA-I-DSC1 complexes, e.g. one of the complexes disappears completely in 3 min (arrowheads in Figure 2C ).
The specific binding and co-migration strongly suggest that DSC1 can regulate apoA-I function in HDL biogenesis.
Apolipoprotein A-I-desmocollin 1 binding prevents high-density lipoprotein biogenesis DSC1-containing PM microdomains are rich in cholesterol ( Figure  1D) . Therefore, the apoA-I-DSC1 binding may facilitate cholesterol removal by apoA-I. To test this hypothesis, an apoA-I-mediated cholesterol efflux assay was performed in HEK293 cells transfected with pDSC1. Both DSC1a and DSC1b are synthesized as pre-proproteins that are matured by proteolytic cleavage. A closely spaced doublet band exhibits the upper proprotein and the lower mature protein ( Figure 3A , lanes 2 and 3). HEK293 cells express endogenous DSC1b ( Figure 3A , lanes 1 and 4), and overexpression of either DSC1a or DSC1b in HEK293 significantly increased apoA-I binding capacity ( Figure 3A , lanes 2 and 3). Interestingly however, apoA-I-mediated cholesterol efflux from HEK293 cells was almost absent, regardless of the levels of DSC1 expression and DSC1-dependent apoA-I binding ( Figure 3A, lanes 1-3) . In contrast, HEK239 overexpressing ABCA1 increased both apoA-I binding and apoA-I-mediated cholesterol efflux ( Figure 3A , lane 4). Co-overexpression of ABCA1 and DSC1 shows that ABCA1-and DSC1-dependent apoA-I binding are additive but that apoA-I-mediated cholesterol efflux from the cooverexpressing cells is not significantly different from ABCA1-only overexpressing cells ( Figure 3A , lanes 5 and 6). The results of cholesterol efflux measured for 24 h ( Figure 3A ) are similar to those for 6 h (see Supplementary material online, Figure S4 ). Of note, ABCA1 expression levels in the cells co-transfected with pABCA1-GFP/ pDSC1a ( Figure 3A , lane 5) or pABCA1-GFP/pDSC1b ( Figure 3A , lane 6) are significantly higher than in the cells co-transfected with ABCA1-GFP/control plasmid ( Figure 3A , lane 4). This is due to an inverse relationship between transfection efficiency and plasmid DNA size: transfection efficiency decreases in the order of 4.7kb control plasmid > 6.5 kb pDSC1b > 6.7 kb pDSC1a > 11.7 kb pABCA1-GFP, thus less pABCA1-GFP is delivered into cells in pABCA1-GFP/ control plasmid vs. pABCA1-GFP/pDSC1 co-transfection when the same amount of each plasmid DNA is used. Similarly, DSC1 expression levels are higher in the lanes 5 and 6 vs. the lanes 2 and 3 of Figure 3A . These results suggest that DSC1 and ABCA1 independently increase apoA-I binding to cells and that apoA-I-mediated cholesterol removal occurs through ABCA1-dependent apoA-I binding pDSC1a, pDSC1b, pABCA1-GFP, or in combinations as indicated. Two days after the transfection, cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 1 mg/ml bovine serum albumin (DMEM/BSA) overnight to deplete serum-derived apoA-I. The cells were incubated with DMEM/BSA containing 5 lg/ml apoA-I for 1 h at 37 C. After extensive washing, the cells were lysed to determine the levels of indicated proteins by immunoblotting. Numeric values shown below the apoA-I blot represent the densities of apoA-I bands normalized to tubulin and relative to mock-transfected cells. In parallel, HEK293 cells labelled with 0.2 lCi/ml of [ 3 H]-cholesterol were subjected to the same transfection scheme. Two days after the transfection, cells were incubated with DMEM/BSA containing 5 lg/ml apoA-I for 24 h to measure apoA-I-mediated cholesterol efflux. Results are displayed as a scatter plot with the mean of quadruplicate determinations. One-way analysis of variance with Tukey's post hoc correction was performed to compute multiplicity-adjusted P-values. (B) Stable HEK293 cell lines expressing shRNAs targeting DSC1 (shDSC1) or shRNAs targeting none (shCont) were transfected with mock or pABCA1-GFP constructs as indicated. Two days after the transfection, cells were incubated with DMDM/BSA for 24 h prior to determining DSC1, ABCA1 and tubulin expression levels by immunoblotting. In parallel, apoA-I-mediated cholesterol efflux assay was performed, and the results were analysed as described in (A). (C) Control HEK293 cells (Cont) and CRISPR/Cas9-mediated DSC1-targeted HEK293 cells (CRISPR-DSC1) were transfected with mock or pABCA1-GFP constructs as indicated. Two days after the transfection, cells were incubated with DMDM/BSA for 24 h prior to determining DSC1, ABCA1 and tubulin expression levels by immunoblotting. In parallel, apoA-I-mediated cholesterol efflux assay was performed and the results were analyzed as described in (A). (D) Primary human skin fibroblasts were labelled with 0.2 lCi/ml of [ but not through DSC1-dependent apoA-I binding. Therefore, extracellular levels of apoA-I and the ABCA1/DSC1 ratio in the PM may be key determinants of HDL biogenesis.
This apoA-I-DSC1 binding suggests that the DSC1 microdomain may sequester PM cholesterol, making it unavailable for efflux via the ABCA1 microdomain. DSC1 may thus function as a negative regulator of the apoA-I-mediated cholesterol removal pathway, and therefore, reducing DSC1 expression or blocking apoA-I-DSC1 interactions may enhance HDL biogenesis. We tested this hypothesis by silencing endogenous DSC1 expression in HEK293 cells. DSC1 protein levels were significantly reduced in cells stably expressing DSC1-targeting shRNAs (shDSC1) compared with cells stably expressing nontargeting control shRNAs (shCont) ( Figure 3B, lanes 1 and 2) . The near absence of apoA-I-mediated cholesterol efflux from these cells confirms that cholesterol removal by apoA-I does not occur without ABCA1. When the cells were transfected with pABCA1-GFP, shDSC1 cells maintained higher levels of ABCA1 protein and showed greater ability to promote apoA-I-mediated cholesterol efflux, compared with shCont cells ( Figure 3B, lanes 3 and 4) . To verify the results, the DSC1 gene in HEK293 cells was targeted using the CRISPR/Cas9 system. 17 This gene-targeting approach achieved more effective suppression of DSC1 expression than shRNA ( Figure 3C , lanes 1 and 2). Along with the greater reduction in DSC1, CRISPR/Cas9-mediated DSC1-targeted (CRISPR-DSC1) cells showed more effective ABCA1-dependent cholesterol efflux to apoA-I ( Figure 3C , lanes 3 and 4) compared with shDSC1 cells ( Figure 3B, lanes 3 and 4) . The results of cholesterol efflux measured for 24 h ( Figure 3C ) are similar to those for 6 h (see Supplementary material online, Figure S5 ). Fluorescence microscopic observation of pABCA1-GFP-transfected CRISPR-DSC1 and control cells showed a similar number of GFP-positive cells, indicating that the difference in ABCA1 protein levels ( Figure 3C , lane 3 vs. 4) is not due to the transfection efficiency of pABCA1-GFP. These DSC1 silencing studies show that the loss of DSC1 mass coincides with the gain of ABCA1 mass and function, suggesting that reduction of apoA-I-DSC1 binding increases apoA-I access to ABCA1-created apoA-I binding sites, where apoA-I protects ABCA1 from degradation and removes cholesterol for the formation of HDL particles. 18 If the loss of DSC1 redistributes PM cholesterol so as to increase cholesterol levels in PM microdomains containing ABCA1, ABCA1 may also be stabilized by the increased cholesterol.
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Determination of apolipoprotein A-I-binding site on desmocollin 1
To test whether the inhibition of apoA-I-DSC1 interactions is sufficient to promote ABCA1-dependent cholesterol efflux to apoA-I, primary HSFs were treated with anti-DSC1 antibody for 1 h prior to performing apoA-I-mediated cholesterol efflux assay. As seen in Figure 3D , cells pre-treated with an anti-DSC1 antibody directed against a portion (amino acid residues 558-681) of the DSC1 extracellular region markedly enhanced cholesterol efflux to apoA-1, whereas an anti-DSG1 antibody developed against whole DSG1 protein had no effect. These results suggest that apoA-I may bind within the residues 558-681 of DSC1. The DSC1 extracellular region comprises five extracellular cadherin repeats (EC1-5) 20 and the residues 558-681 correspond to a part of the EC4 plus the entire EC5 repeats, suggesting that the EC4 and/or EC5 repeats may responsible for the binding of apoA-I. Considering the large size of antibody molecules that are approximately 150 kDa and glycosylated, it is also conceivable that steric hindrance induced by antibody binding to the EC4 and/or EC5 repeats may interfere apoA-I binding to EC1-3 repeats.
To investigate which EC repeat of DSC1 binds apoA-I, plasmids encoding a series of truncated DSC1b proteins lacking EC1 to EC1-5 repeats were constructed ( Figure 4A ). HEK293 cells overexpressing full-length or truncated DSC1b-GFP protein were incubated with 
apoA-I for 1 h at 37
C prior to extensive washing and lysis of the cells. The lysate was subjected to anti-GFP immunoblotting to determine DSC1b-GFP expression levels and anti-apoA-I immunoblotting to measure the apoA-I amount bound to the cells. As DSC1 is synthesized as a pre-proprotein, the triplet DSC1b-GFP bands exhibit the largest pre-proprotein, the intermediate proprotein and the smallest mature protein ( Figure 4B ). As shown in Figure 4B , a markedly increased amount of apoA-I binds to cells overexpressing the full- Apolipoprotein A-I-desmocollin 1 binding is associated with human atherosclerosis
The relevance of apoA-I-DSC1 binding to human atherosclerosis was investigated by performing immunohistochemical staining for apoA-I and DSC1 on coronary artery sections obtained from patients with coronary atherosclerosis. Early stage atherosclerotic lesions characterized by intimal thickening were weakly and sparsely stained for apoA-I and DSC1 ( Figure 5 ). In intermediate-stage lesions, densely concentrated apoA-I staining in the lipid core periphery overlapped Figure 5 ), suggesting that arterial cells co-localizing apoA-I and DSC1 likely die and contribute to the formation of cholesterol-laden necrotic cores. The association between increased DSC1 expression levels and lesion progression was also observed in human carotid atherosclerosis (see Supplementary material online, Figure S6 ), suggesting that DSC1 may play important roles in the development of atherosclerotic lesions in general. In support, DSC1 is expressed in CD68-immunopositive cells that play crucial roles in all stages and sites of atherosclerosis ( Figure 6A ). 21 CD68 is a pan-macrophage marker and anti-DSC1 immunoblotting shows that differentiation of human THP-1 monocytes into macrophages is associated with up-regulation of DSC1 expression ( Figure 6B ). These results suggest that DSC1 expressed in macrophages in atherosclerotic lesions may drive prevention of HDL biogenesis, cholesterol deposition, cell death, and thus disease progression.
Discussion
We have shown that DSC1 located in cholesterol-and SM-rich microdomains binds apoA-I and prevents apoA-I from forming HDL particles. DSC1-containing microdomains therefore counteract ABCA1-created microdomains that facilitate apoA-I binding for HDL formation. These two apoA-I binding but functionally opposing PM microdomains may regulate HDL biogenesis and PM cholesterol levels. An illustration of this model is shown in Take home figure.
Desmosomes are intercellular junctions formed by direct binding between desmosomal cadherins, DSG and DSC, at the cellcell interface. 22 In humans, DSG 1-4 and DSC 1-3 isoforms are encoded by separate genes clustered on chromosome 18. 20 Moreover, each of the three DSCs exists in two alternatively spliced forms (a and b), differing only in the carboxyl terminus.
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Although isoform-specific functions remain to be elucidated, genetic or functional defects in all desmosomal cadherins except DSC1 have been linked to human diseases. 20 Dsc1 -/-mice show localized defects in the epidermal barrier, but assemble desmosomes normally without compensatory up-regulation of other DSC isoforms. 15 Dsc1 knock-in mice that express a truncated DSC1 lacking the carboxyl-terminal tail differentiating DSC1a from DSC1b are free of any phenotype observed in Dsc1 -/-mice. 13 It has been reported that the carboxyl-terminal sequences contained in the longer DSC1a but not in the shorter DSC1b are necessary for the recruitment of desmoplakin and plakoglobin to assemble desmosomes. 23 These results support the general agreement that DSC1 is dispensable for the assembly of desmosomes and the notion that DSC1 may harbour its essential functional elements in the extracellular and transmembrane domains. This study shows that apoA-I binds to the DSC1 extracellular domain (Figure 4 ), suggesting that a role of DSC1 in desmosomes is probably to prevent HDL biogenesis for the conservation of PM cholesterol. DSC1 is most abundantly expressed in the skin and Dsc1 -/-mice show defects in skin barrier function, 15 suggesting that DSC1-dependent maintenance of high cholesterol levels in desmosomes may be necessary for the formation of a waterimpermeable skin barrier. It is widely believed that desmosomes are largely confined to epithelia and cardiac muscle and are absent from leucocytes and endothelia, therefore our demonstration of DSC1 expression in macrophages ( Figure 6 ) and atherosclerotic plaques ( Figure 5 and see Supplementary material online, Figure S6 ) appears quite novel. DSC1 expression in arterial intima could be a maladaptive process: DSC1-containing desmosomes may be assembled to maintain intimal tissue integrity or repair damaged intima but may result in building up cholesterol by impairing HDL biogenesis. Considering that atherosclerosis is a cholesterol depositiondriven chronic inflammatory disease and that HDL biogenesis is the major mechanism to remove excess cholesterol from macrophages, 4, 6 DSC1-attributed impairment of HDL biogenesis from intimal macrophages is a highly likely contributor to the progression of atherosclerosis. It has been reported that atherosclerotic plaque-laden human aorta contains at least 100-fold more apoA-I compared with normal aorta and that the vast majority of apoA-I within the plaque is functionally impaired and not associated with HDL particles. 
